Social media addiction (SMA), also termed problematic social media use, is a behavioral addiction characterized by compulsive engagement with social media platforms despite negative consequences. Although not formally recognized in DSM-5-TR or ICD-11 (only Internet Gaming Disorder is included), it shares neurobiological and behavioral features with established addictions and is recognized in research and clinical practice. Affects 5-15% of adolescents and young adults globally, with platforms designed using variable reward schedules, infinite scroll, and notification systems exploiting dopaminergic reward circuits.
Pathophysiology involves dysregulation of dopaminergic reward circuits (ventral tegmental area, nucleus accumbens, prefrontal cortex), with platform features (likes, comments, notifications) acting as variable ratio reinforcers similar to gambling. Comorbidities include depression (bidirectional relationship), generalized and social anxiety, FOMO (fear of missing out), body dysmorphic disorder, eating disorders, ADHD, sleep disorders, and other behavioral addictions. Risk factors: adolescence (developing prefrontal cortex), introversion or extreme extroversion, low self-esteem, social anxiety, peer influence, parental modeling, accessibility (smartphone ownership), and pre-existing mental health conditions.
Assessment uses validated tools: Bergen Social Media Addiction Scale (BSMAS, 6 items based on Griffiths components), Social Media Disorder Scale, Smartphone Addiction Scale (SAS-SV). Clinical interview explores time use, functional impairment (sleep, school/work, relationships, physical activity), failed attempts to reduce use, withdrawal symptoms (anxiety, irritability when offline), preoccupation, lying about use, and using as escape. Treatment is multimodal: cognitive-behavioral therapy (identifying triggers, cognitive restructuring, behavioral substitution, scheduled use, app blockers), motivational interviewing (enhancing motivation for change), digital detox (graduated reduction or complete abstinence period), family-based therapy (parental involvement, family media plans, screen time limits), school-based prevention programs, mindfulness-based interventions, treating comorbid conditions (SSRIs for depression/anxiety, stimulants for ADHD), and addressing FOMO through values clarification and meaningful offline activities. Pharmacotherapy is reserved for comorbid conditions; no specific medications are FDA-approved for SMA. Public health interventions include platform regulation (age verification, design ethics, time-limit defaults), digital literacy education, and parental guidance.